AZ, Daiichi get FDA nod for Dato-DXd in breast cancer
AstraZeneca and Daiichi Sankyo have claimed FDA approval for a second antibody-drug conjugate (ADC) for breast cancer, hoping to build on the success of a partnership that already spawned a blockbuster drug. The US regulator has cleared TROP2-directed ADC …